About Her—HER2, that is

On April 17, the FDA approved a new drug called Tukysa (tucatinib) for use in combination with chemotherapy for patients with HER2-positive breast cancer that has metastasized to the brain. All new treatment options are good news, but this is particularly good news because: HER2-positive breast cancer is not as common as HER2-negative, thankfully, because …

About Her—HER2, that is Read More »